Skip to main content

Skin & Melanoma

Protocols

Adjuvant

SMAJDT

Adjuvant Treatment of Stage III and IV, BRAF mutated, fully resected Melanoma Using daBRAFenib and Trametinib

SMAJNIV

Adjuvant Treatment of Resected Stage III – IV NED Melanoma Using Nivolumab

SMAJNIV4

Adjuvant Treatment of Resected Stage III - IV NED Melanoma Using 4-Weekly Nivolumab

SMAJPEM

Adjuvant Treatment of Resected Stage III – IV NED Melanoma Using Pembrolizumab

SMAJPEM6

Adjuvant Treatment of Resected Stage III – IV NED Melanoma Using 6-Weekly Pembrolizumab

Advanced - immunotherapy

SMAVFIPI

First-Line Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab


SMAVIPI

Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab

SMAVIPNI

Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab and Nivolumab

SMAVNIV

Treatment of Unresectable or Metastatic Melanoma Using Nivolumab

SMAVNIV4

Treatment of Unresectable or Metastatic Melanoma Using 4-Weekly Nivolumab

SMAVPEM

Treatment of Unresectable or Metastatic Melanoma Using Pembrolizumab


SMAVPEM6

Treatment of Unresectable or Metastatic Melanoma Using 6-Weekly Pembrolizumab

Advanced - targeted therapy

SMAVDAB

Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Dabrafenib 

SMAVDT

Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using daBRAFenib and Trametinib


SMAVI

Treatment of Advanced C-Kit Positive Melanoma Using iMAtinib 


SMAVTRA

Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Trametinib


SMAVVC

Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using vemURAFenib and cobimetinib

SMAVVEM

Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Vemurafenib

Advanced - other

SMAVTMZ

Palliative Therapy for Malignant Melanoma with Brain Metastases Using Temozolomide

SMDTIC

Therapy for Metastatic Malignant Melanoma Using High Dose Single Agent Dacarbazine (DTIC)

Local therapy

SMILALD

Treatment of In-Transit Melanoma using Intralesional Aldesleukin (IL-2)

SMIMI

Topical Immunotherapy for In-Transit Melanoma Metastases, Cutaneous Lymphoma, Basal Cell Carcinoma Using Imiquimod

SMPDT

Topical Therapy for Skin Cancer with PDT (Photodynamic Therapy)

Basal cell carcinoma

SMAVVIS

Treatment of Metastatic or Locally Advanced Basal Cell Carcinoma Using Vismodegib

Merkel cell carcinoma

SMMCCAVE

Second-Line Treatment of Recurrent or Metastatic Merkel Cell Carcinoma Using Avelumab

SMMCCPE

Treatment of recurrent or metastatic Merkel cell carcinoma (MCC) with CISplatin and Etoposide

Cutaneous Squamous cell carcinoma

SMAVCEM

Treatment of Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma using Cemiplimab

Terms of use

The information contained in these documents is a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. 

Use of these documents is at your own risk and is subject to BC Cancer's Terms of Use.

Tab Heading
Tab Heading
SOURCE: Skin & Melanoma ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2022 Provincial Health Services Authority